Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells

Yijiang Shi, Tracy R. Daniels-Wells, Patrick Frost, Jihye Lee, Richard S. Finn, Carolyne Bardeleben, Manuel L. Penichet, Michael E. Jung, Joseph Gera, Alan Lichtenstein

Cancer Res (2016) 76 (19): 5822–5831.

https://doi.org/10.1158/0008-5472.CAN-16-1019

Published: 02 October 2016

View articletitled, Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells

Includes: Supplementary data

Journal Articles

Abstract 5132: Targeting hypoxia-mediated gene transcription with a novel polyamide drug designed to disrupt the HIF1α/β heterodimer binding overcomes resistance to hypoxia in myeloma cell lines

Veena S. Mysore, Nicholas G. Nickols, Jerzy Szablowski, Peter Dervan, Alan Lichtenstein, Patrick J. Frost

Cancer Res (2014) 74 (19_Supplement): 5132.

https://doi.org/10.1158/1538-7445.AM2014-5132

Published: 01 October 2014

View articletitled, Abstract 5132: Targeting hypoxia-mediated gene transcription with a novel polyamide drug designed to disrupt the HIF1α/β heterodimer binding overcomes resistance to hypoxia in myeloma cell lines

Journal Articles

Abstract 1874: Phosphatidylcholine synthesis as a potential therapeutic target in multiple myeloma.

Carolyne Bardeleben, Alan Lichtenstein

Cancer Res (2013) 73 (8_Supplement): 1874.

https://doi.org/10.1158/1538-7445.AM2013-1874

Published: 15 April 2013

View articletitled, Abstract 1874: Phosphatidylcholine synthesis as a potential therapeutic target in multiple myeloma.

Journal Articles

Abstract 1959: Identification of inhibitors specific for torc2 as strategy to overcome feedback erk activation in multiple myeloma cells when treated with second generation mtor inhibitors

Bao Hoang, Angelica Benavides, Andrew Bernath, Cheri Cloninger, Nicholas Artinian, Tariq Bashir, Joe Gera, Alan Lichtenstein

Cancer Res (2011) 71 (8_Supplement): 1959.

https://doi.org/10.1158/1538-7445.AM2011-1959

Published: 15 April 2011

View articletitled, Abstract 1959: Identification of inhibitors specific for torc2 as strategy to overcome feedback erk activation in multiple myeloma cells when treated with second generation mtor inhibitors

Journal Articles

Abstract 1595: Phosphomimetic mutation of hnRNP A1 inhibits AKT-dependent IRES function and results in mTOR inhibitor sensitivity

Jheralyn Martin, Janine Masri, Cheri Cloninger, Brent Holmes, Alan Lichtenstein, Joseph F. Gera

Cancer Res (2010) 70 (8_Supplement): 1595.

https://doi.org/10.1158/1538-7445.AM10-1595

Published: 15 April 2010

View articletitled, Abstract 1595: Phosphomimetic mutation of hnRNP A1 inhibits AKT-dependent IRES function and results in mTOR inhibitor sensitivity

Journal Articles

Abstract #1877: Impact of autophagy on multiple myeloma cell viability

Bao Hoang, Angelica Benavides, Yijiang Shi, Patrick Frost, Alan Lichtenstein

Cancer Res (2009) 69 (9_Supplement): 1877.

Published: 01 May 2009

View articletitled, Abstract #1877: Impact of autophagy on multiple myeloma cell viability

Journal Articles

Bcl-B expression in human epithelial and non-epithelial malignancies.

Cancer Res (2008) 68 (9_Supplement): 2180.

Published: 01 May 2008

View articletitled, Bcl-B expression in human epithelial and non-epithelial malignancies.

Journal Articles

Akt activity regulates the function of internal ribosome entry sites (IRES) in the VEGF 5'UTR

Patrick Frost, Bao Hoang, YiJiang Shi, Sanjai Sharma, Angelica Benavides, Alan Lichtenstein

Cancer Res (2008) 68 (9_Supplement): 290.

Published: 01 May 2008

View articletitled, Akt activity regulates the function of internal ribosome entry sites (IRES) in the VEGF 5'UTR

Journal Articles

The early growth response 3 gene (egr3), located at 8p21, is a possible tumor suppressor in head and neck cancer (HNC).

Sanjai Sharma, Xiaofeng Zhou, David Wong, Alan Lichtenstein

Cancer Res (2007) 67 (9_Supplement): 3663.

Published: 01 May 2007

View articletitled, The early growth response 3 gene (egr3), located at 8p21, is a possible tumor suppressor in head and neck cancer (HNC).

Journal Articles

Akt phosphorylates and negatively regulates hnRNPA1-mediated control of cyclin D1 and c-myc translation in response to rapamycin

Oak Jo, Jheralyn Martin, Andrew Bernath, Janine Masri, Alan Lichtenstein, Joseph Gera

Cancer Res (2007) 67 (9_Supplement): 2561.

Published: 01 May 2007

View articletitled, Akt phosphorylates and negatively regulates hnRNPA1-mediated control of cyclin D1 and c-myc translation in response to rapamycin

Journal Articles

Mechanism by Which Mammalian Target of Rapamycin Inhibitors Sensitize Multiple Myeloma Cells to Dexamethasone-Induced Apoptosis

Huajun Yan, Patrick Frost, Yijiang Shi, Bao Hoang, Sanjai Sharma, Myrna Fisher, Joseph Gera, Alan Lichtenstein

Cancer Res (2006) 66 (4): 2305–2313.

https://doi.org/10.1158/0008-5472.CAN-05-2447

Published: 17 February 2006

View articletitled, Mechanism by Which Mammalian Target of Rapamycin Inhibitors Sensitize Multiple Myeloma Cells to Dexamethasone-Induced Apoptosis

Journal Articles

Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer

Harnisha N. Dalwadi, Kostyantyn Krysan, Nathalie Heuze-Vourc’h, Mehis Põld, Mariam Dohadwala, David Elashoff, Sherven Sharma, Nicholas Cacalano, Alan Lichtenstein, Steven Dubinett

Cancer Res (2005) 65 (9_Supplement): 1237–1238.

Published: 01 May 2005

View articletitled, Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer

Journal Articles

Oncogenic RAS-mediated induction of cyclooxygenase-2 (COX-2) promotes adhesion of multiple myeloma cells to fibronectin

Bao Hoang, Li Zhu, Steven M. Dubinett, Alan Lichtenstein

Cancer Res (2005) 65 (9_Supplement): 892.

Published: 01 May 2005

View articletitled, Oncogenic RAS-mediated induction of cyclooxygenase-2 (COX-2) promotes adhesion of multiple myeloma cells to fibronectin

Journal Articles

Enhanced Sensitivity of Multiple Myeloma Cells Containing PTEN Mutations to CCI-779

Yijiang Shi, Joseph Gera, Liping Hu, Jung-hsin Hsu, Robert Bookstein, Weiqun Li, Alan Lichtenstein

Cancer Res (2002) 62 (17): 5027–5034.

Published: 01 September 2002

View articletitled, Enhanced Sensitivity of Multiple Myeloma Cells Containing PTEN Mutations to CCI-779

Journal Articles

The Phosphatidylinositol 3-Kinase/AKT Kinase Pathway in Multiple Myeloma Plasma Cells: Roles in Cytokine-dependent Survival and Proliferative Responses

Yiping Tu, Agnes Gardner, Alan Lichtenstein

Cancer Res (2000) 60 (23): 6763–6770.

Published: 01 December 2000

View articletitled, The Phosphatidylinositol 3-Kinase/AKT Kinase Pathway in Multiple Myeloma Plasma Cells: Roles in Cytokine-dependent Survival and Proliferative Responses

Journal Articles

BCL-X Expression in Multiple Myeloma: Possible Indicator of Chemoresistance

Yiping Tu, Steven Renner, Feng-hao Xu, Alex Fleishman, Jeremy Taylor, Jeffrey Weisz, Robert Vescio, Matthew Rettig, James Berenson, Stanislaw Krajewski, John C. Reed, Alan Lichtenstein

Cancer Res (1998) 58 (2): 256–262.

Published: 01 January 1998

View articletitled, BCL-X Expression in Multiple Myeloma: Possible Indicator of Chemoresistance

Journal Articles

Interferon-induced Increase in Sensitivity of Ovarian Cancer Targets to Lysis by Lymphokine-activated Killer Cells: Selective Effects on HER2/neu-overexpressing Cells

Catherine Fady, Agnes M. Gardner, Joseph F. Gera, Alan Lichtenstein

Cancer Res (1992) 52 (4): 764–769.

Published: 01 February 1992

View articletitled, Interferon-induced Increase in Sensitivity of Ovarian Cancer Targets to Lysis by Lymphokine-activated Killer Cells: Selective Effects on HER2/neu-overexpressing Cells

Journal Articles

Resistance of Human Ovarian Cancer Cells to Tumor Necrosis Factor and Lymphokine-activated Killer Cells: Correlation with Expression of HER2/neu Oncogenes

Alan Lichtenstein, James Berenson, Joseph F. Gera, Kristine Waldburger, Otoniel Martinez-Maza, Jonathan S. Berek

Cancer Res (1990) 50 (22): 7364–7370.

Published: 01 November 1990

View articletitled, Resistance of Human Ovarian Cancer Cells to Tumor Necrosis Factor and Lymphokine-activated Killer Cells: Correlation with Expression of HER2/neu Oncogenes

Journal Articles

Intraperitoneal Administration of Human Recombinant Interferon-α in Patients with Ovarian Cancer: Effects on Lymphocyte Phenotype and Cytotoxicity

Alan Lichtenstein, Celsa Spina, Jonathan S. Berek, Tyler Jung, Jacob Zighelboim

Cancer Res (1988) 48 (20): 5853–5859.

Published: 01 October 1988

View articletitled, Intraperitoneal Administration of Human Recombinant Interferon-α in Patients with Ovarian Cancer: Effects on Lymphocyte Phenotype and Cytotoxicity

Journal Articles

Natural Killer Cell Cytotoxicity in the Peripheral Blood, Cervical Lymph Nodes, and Tumor of Head and Neck Cancer Patients

Robert A. Mickel, David J. Kessler, Jeremy M. G. Taylor, Alan Lichtenstein

Cancer Res (1988) 48 (17): 5017–5022.

Published: 01 September 1988

View articletitled, Natural Killer Cell Cytotoxicity in the Peripheral Blood, Cervical Lymph Nodes, and Tumor of Head and Neck Cancer Patients

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Cytotoxic Properties of a DEPTOR-mTOR Inhibitor in Multiple Myeloma Cells

Abstract 5132: Targeting hypoxia-mediated gene transcription with a novel polyamide drug designed to disrupt the HIF1α/β heterodimer binding overcomes resistance to hypoxia in myeloma cell lines

Abstract 1874: Phosphatidylcholine synthesis as a potential therapeutic target in multiple myeloma.

Abstract 1959: Identification of inhibitors specific for torc2 as strategy to overcome feedback erk activation in multiple myeloma cells when treated with second generation mtor inhibitors

Abstract 1595: Phosphomimetic mutation of hnRNP A1 inhibits AKT-dependent IRES function and results in mTOR inhibitor sensitivity

Abstract #1877: Impact of autophagy on multiple myeloma cell viability

Bcl-B expression in human epithelial and non-epithelial malignancies.

Akt activity regulates the function of internal ribosome entry sites (IRES) in the VEGF 5'UTR

The early growth response 3 gene (egr3), located at 8p21, is a possible tumor suppressor in head and neck cancer (HNC).

Akt phosphorylates and negatively regulates hnRNPA1-mediated control of cyclin D1 and c-myc translation in response to rapamycin

Mechanism by Which Mammalian Target of Rapamycin Inhibitors Sensitize Multiple Myeloma Cells to Dexamethasone-Induced Apoptosis

Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer

Oncogenic RAS-mediated induction of cyclooxygenase-2 (COX-2) promotes adhesion of multiple myeloma cells to fibronectin

Enhanced Sensitivity of Multiple Myeloma Cells Containing PTEN Mutations to CCI-779

The Phosphatidylinositol 3-Kinase/AKT Kinase Pathway in Multiple Myeloma Plasma Cells: Roles in Cytokine-dependent Survival and Proliferative Responses

BCL-X Expression in Multiple Myeloma: Possible Indicator of Chemoresistance

Interferon-induced Increase in Sensitivity of Ovarian Cancer Targets to Lysis by Lymphokine-activated Killer Cells: Selective Effects on HER2/neu-overexpressing Cells

Resistance of Human Ovarian Cancer Cells to Tumor Necrosis Factor and Lymphokine-activated Killer Cells: Correlation with Expression of HER2/neu Oncogenes

Intraperitoneal Administration of Human Recombinant Interferon-α in Patients with Ovarian Cancer: Effects on Lymphocyte Phenotype and Cytotoxicity

Natural Killer Cell Cytotoxicity in the Peripheral Blood, Cervical Lymph Nodes, and Tumor of Head and Neck Cancer Patients

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only